Boston criteria v2.0 for cerebral amyloid angiopathy without hemorrhage: An MRI-neuropathological

validation study

Aaron Switzer^{1,2}, MD; Antreas Charidimou,³MD, PhD; Stuart J. McCarter¹, M.D.; Prashanthi Vemuri⁴, PhD;

Aivi Nguyen,⁵,MD; Scott A. Przybelski⁶; Timothy G. Lesnick⁶; Alejandro A. Rabinstein,¹ MD; Robert D.

Brown,¹ MD; David S. Knopman,¹MD; Ronald C. Petersen¹, MD, PhD; Clifford R. Jack,⁴ Jr., MD; R. Ross

Reichard,⁵ MD; Jonathan Graff-Radford¹, MD

Affiliations:

- 1 Department of Neurology, Mayo Clinic, Rochester, MN, USA
- 2 University of Calgary, Calgary, AB, Canada
- 3 Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
- 4- Department of Radiology, Mayo Clinic, Rochester, MN, USA
- 5 Department of Pathology, Division of Neuropathology, Rochester, MN, USA
- 6- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA

Total word count (including Title Page, Abstract, Text, References, Tables and Figure Legends): 4321

1 Abstract:

2	BACKGROUND: Updated criteria for the clinical-MRI diagnosis of cerebral amyloid angiopathy (CAA)
3	have recently been proposed. However, their performance in individuals without intracerebral
4	hemorrhage (ICH) or transient focal neurological episodes (TFNE) is unknown. We assessed the
5	diagnostic performance of the Boston criteria version 2.0 for CAA diagnosis in a cohort of individuals
6	presenting without symptomatic ICH.
7	METHODS: Fifty-four participants from the Mayo Clinic Study of Aging or Alzheimer's Disease Research
8	Center were included if they had an antemortem MRI with gradient-recall echo sequences and a brain
9	autopsy with CAA evaluation. Performance of the Boston criteria v2.0 was compared to v1.5 using
10	histopathologically verified CAA as the reference standard.
11	RESULTS: Median age at MRI was 75 years (IQR 65-80) with 28/54 participants having histopathologically
12	verified CAA (i.e., moderate-to-severe CAA in at least 1 lobar region). The sensitivity and specificity of
13	the Boston criteria v2.0 were 28.6% (95%CI: 13.2-48.7%) and 65.3% (95%CI: 44.3-82.8%) for probable
14	CAA diagnosis (AUC 0.47) and 75.0% (55.1-89.3) and 38.5% (20.2-59.4) for any CAA diagnosis (possible +
15	probable; AUC: 0.57), respectively. The v2.0 Boston criteria was not superior in performance compared
16	to the prior v1.5 criteria for either CAA diagnostic category.
17	CONCLUSIONS: The Boston criteria v2.0 have low accuracy in patients who are asymptomatic or only
18	have cognitive symptoms Additional biomarkers need to be explored to optimize CAA diagnosis in
19	this population.
20	KEY WORDS: Cerebral Amyloid Angiopathy (CAA); MRI; intracerebral hemorrhage (ICH); Mayo Clinic

- 21 Study of Aging (MCSA)
- 22

23 Introduction:

24	Cerebral amyloid angiopathy (CAA) is a common small vessel pathology, characterized by different
25	degrees of cerebrovascular amyloid- β deposition in cortical and leptomeningeal vessels. ¹ CAA is a
26	common cause of spontaneous lobar intracerebral hemorrhage (ICH), especially in the elderly and a key
27	vascular contributor to cognitive impairment and dementia, including Alzheimer's disease. The Boston
28	criteria were developed as a set of clinical-MRI features to allow the diagnosis of CAA during life, in the
29	absence of neuropathological analysis from post-mortem examination or biopsy (which still remains the
30	gold standard for the definite diagnosis of the disease). ² Based on the presence of multiple strictly lobar
31	cerebral microbleeds (CMBs), the initial iteration of the Boston criteria (v1.0), allowed for a diagnosis of
32	probable CAA (i.e., indicative of probable underlying CAA pathology) primarily in patients with
33	symptomatic ICH ³ . The probable CAA diagnostic category remains the cornerstone for defining CAA in
34	both the clinical and research setting. ² A modified version of the Boston Criteria (v1.5) further
35	incorporated cortical superficial siderosis (cSS), a characteristic (and novel at the time) hemorrhagic
36	marker of CAA, aiming to improve diagnostic accuracy. ⁴
37	Advances in unraveling the much wider than previously appreciated clinical-MRI spectrum of CAA,
38	coupled with important limitations of prior Boston criteria validation studies (i.e., small sample sizes,
39	inclusion mainly of patients with prior ICH, and limited evaluation of the spectrum of CAA MRI
40	markers ^{2,5}) prompted a large multicentre effort to update and validate the Boston criteria. The Boston
41	criteria (v2.0) introduced non-hemorrhagic markers, white matter hyperintensity multi-spot (WMH-MS)
42	pattern ⁶ and MRI-visible perivascular spaces in the centrum semiovale (CSO-PVS), ⁷ in addition to
43	hemorrhagic markers, to improve sensitivity without significantly compromising specificity when
44	compared to prior versions of the criteria. ⁸

45	All previous versions of the Boston Criteria, including v2.0, were calibrated to identify more severe,				
46	bleeding-prone, cases of CAA. However, the performance of the Boston criteria v2.0 is uncertain in a				
47	population of cognitively unimpaired individuals and patients with MCI or dementia, presumably				
48	representing less severe CAA. There are few studies assessing the performance of any iteration of the				
49	Boston criteria in this population. ^{9,10} Therefore, the aim of this study was to evaluate the diagnostic				
50	performance of the Boston criteria v2.0, in a population without symptomatic ICHs or transient focal				
51	neurological episodes (TFNE), which represented the majority of patients in the recent validation study. ⁸				
52	Methods:				
53	Study cohort and eligibility criteria				
54	This is a retrospective cohort study including participants enrolled in either the Mayo Clinic Study of				
55	Aging (MCSA) ¹¹ or the Mayo Alzheimer's Disease Research Center (ADRC). Participants were included if				
56	they had a MRI T2* gradient-recall echo sequence (GRE) and a brain autopsy with CAA evaluation. At the				
57	time of antemortem MRI, none of the participants had a history of ICH, TFNE, or CAA-related				
58	inflammation.				
59	MRI analysis				
60	Participants had T1-weighted, T2 FLAIR, and T2*-GRE sequences on a 3-tesla General Electric MRI				
61	scanner between October 2011 and June 2016. Images were assessed for MRI features of CAA (cSS,				
62	WMH-MS pattern, CSO-PVS, and CMBs) according to international rating standards and				
63	recommendations ^{12,13} and blinded to demographic, clinical and neuropathological data. Gradient				
64	recalled echo sequences were reviewed by a trained neurology fellow (ARS) and confirmed by a vascular				
65	neurologist (JGR).				

66	Cortical superficial siderosis was defined as curvilinear hypointensities that track the cortical
67	surface on T2*-weighted GRE, without corresponding hyperintensity on T1-weighted or FLAIR images. ¹⁴
68	They were graded on the following scale: 0-absent, 1-focal (restricted to \leq 3 sulci, or 3-disseminated
69	(involving >4 sulci). ¹⁵

The WMH-MS pattern was defined as >10 circular or ovoid WMHs surrounded by normal subcortical white matter on a FLAIR sequence.⁶ Images were reviewed by a trained neurology fellow (ARS), and each subcortical WMH spot was counted. If there were more than 10 WMH spots, the sign was considered present. WMH spots were not counted if associated with lacunar infarcts, perivascular spaces, or remote intracranial hemorrhages, confluent with a periventricular WMH, or confluent with another subcortical WMH. If the number of WMH spots was borderline (i.e., 10 or 11), the overall WMH pattern was used to determine whether the sign was present or not.

77 Perivascular spaces in the centrum semiovale were defined as round, oval, or linear shaped 78 signal hyperintensity on T2-weighted sequences, or hypointensity on T1-weighted or T2 FLAIR sequences with intensity equal to cerebrospinal fluid.¹⁶ Most participants did not have T2-weighted fast 79 spin echo (FSE) sequences; therefore CSO-PVS were counted on T1-weighted and T2 FLAIR sequences. 80 CSO-PVS were counted following the Wardlaw method.¹⁷ Each axial slice was visually inspected and a 81 82 representative slice with the most visible PVS was chosen in the centrum semiovale. The hemisphere 83 with the most PVS was counted. If the PVS count was >20 in the centrum semiovale, the CSO-PVS sign 84 was considered positive. Fifty-six percent of participants had both T2-FSE and T1-weighted sequences. In 85 this subset of patients, CSO-PVS were counted on both sequences. T1-weighted sequences routinely underestimated the number of PVS compared to T2-FSE (Supplemental Figure 1). To maximize the 86 number of participants in the study, PVS were counted on T1-weighted and T2 FLAIR sequences 87 88 accepting that the true number may be underestimated.

Cerebral microbleeds were defined as a round hypointense lesion on T2*-weighted GRE that was distinct from iron or calcium deposition, or a vessel.¹⁷ CMB grading was performed by a trained imaging analyst and confirmed by a vascular neurologist (JGR). When it was unclear whether a lesion was a CMB or a vessel flow void, it was recorded as a possible CMB. Possible CMBs were not included in our analysis.¹⁸ An in-house, modified automated anatomic-labeling atlas was applied to the T1-weighted sequence and resampled into the GRE image on which the CMBs were graded.¹⁹ CMBs were classified as lobar only or deep/infratentorial.

A random sample of 20 participants were rated for WMH-MS pattern and MRI-visible severe
CSO-PVS by ARS and SM. Interrater reliability showed excellent agreement (Cohen's kappa 0.88 (95%CI:
0.64-1) for WMH-MS sign and 0.83 (95%CI: 0.61-1) for PVS). Participants were classified according to the
Boston criteria v1.5⁴ and v2.0.⁸

100 Neuropathological grading

101 A board-certified neuropathologist (RRR) graded CAA severity based on Love Consensus Criteria.²⁰ Each

102 sample was formalin-fixed, embedded in paraffin, and stained using an amyloid-β antibody.¹⁸ CAA

103 burden was rated in the parenchymal and leptomeningeal areas of each region on a scale of 0-3

104 (0=absent CAA; 1=scant CAA; 2=CAA in \geq 2 arterioles with some circumferential A β ; 3=widespread

105 arteriolar CAA, many with circumferential Aβ). Capillary CAA was rated as present or absent. Forty-eight

106 participants had complete CAA evaluation in all regions; the remainder had partial evaluations with

107 missing data in the following regions: frontal *n*=3, temporal *n*=1, parietal *n*=2, occipital *n*=1, and

108 hippocampus *n*=4.

109 CAA classification and statistical analysis

110 Histopathologically verified CAA, used as the diagnostic reference standard for our analyses, was

defined as at least one region with either parenchymal or leptomeningeal CAA graded 2 or higher

112	according to the above scale. In secondary analyses, different CAA severity cut-offs were used to define				
113	the neuropathologic reference standard for CAA diagnosis, to explore if changes in the diagnostic				
114	performance of either set of criteria are different. Finally, in an explorative analysis of diagnostic				
115	performance, the presence of cognitive impairment, in addition to MRI markers, was required to apply				
116	the criteria for probable or possible CAA.				
117	A participant's baseline characteristics were summarized according to histopathologically				
118	verified CAA status using the mean and standard deviation for continuous variables and proportions for				
119	categorical variables. The diagnostic yield of the Boston criteria against the pathologically verified CAA				
120	reference standard was investigated using sensitivity, specificity, positive predictive value (PPV),				
121	negative predictive value (NPV), and area under the receiver operating characteristic (ROC) curve (AUC).				
122	Differences between the AUCs were tested using Z-tests from the R package pROC. ²¹ The level for				
123	statistical significance was set at 0.05 for all analyses. R version 4.3.1 was used for all analyses.				
124	Data Availability				
125	The data that support the findings of this study are available from the corresponding author, upon				
126	request.				
127	Approvals				
128	The Mayo Clinic Institutional Review Board approved this project. Patients provided written informed				
129	consent for the use of their medical information for research purposes.				
130	Reporting Guidelines				
131	This study followed the STROBE reporting guidelines. ²²				

132 Results:

133	Fifty-four participants (24% female, median age at MRI 75 years) were included in the study. Baseline				
134	characteristics are summarized in Table 1 . The prevalence of moderate-to-severe CAA in at least one				
135	lobar region on brain pathology was 28/54 (52%). Forty-two participants had cognitive impairment				
136	(defined as a Mini-Mental Status Exam score <26). Based on the Boston criteria v2.0, 17 participants met				
137	criteria for probable CAA, and 10 met criteria for possible CAA diagnosis (Table 1). There was a high				
138	prevalence of lobar CMBs (33% of participants). Only 7% had either evidence of cSS or CSO-PVS. Sixty-six				
139	exhibited the WMH-MS pattern. Primary neuropathological diagnoses included Alzheimer's disease,				
140	Lewy body disease, frontotemporal lobar degeneration, primary age-related tauopathy, argyrophilic				
141	grain disease, and prion disease.				
142	Diagnostic performance measures are summarized in Table 2 . Using the Boston criteria v2.0, the				
143	sensitivity and specificity for probable CAA diagnosis (vs. non probable CAA) was 28.6% (95% CI: 13.2-				
144	48.7) and 65.3% (44.3-82.8) respectively, with an AUC of 0.47. Sensitivity and specificity for any CAA				
145	diagnosis (probable or possible CAA vs. no CAA) were 75.0% (95%CI: 55.1-89.3) and 38.5% (95%CI: 20.2-				
146	59.4) respectively, with an AUC of 0.57. There was no statistically significant difference in diagnostic				
147	performance between the Boston criteria v2.0 compared to v1.5 for probable CAA diagnosis (AUC 0.47				
148	[95%CI: 0.34-0.60] vs. AUC 0.51 [0.40-0.62], Z= -0.94, p= 0.35) or any CAA diagnosis (AUC 0.57 [0.44-				
149	0.69] vs. AUC 0.45 [0.32-0.58], Z= 1.7, p= 0.09).				
150	Using the Boston criteria v2.0 with probable CAA as the "rule in" diagnosis, changing the				
151	reference standard to histopathological grade of at least 1 (mild CAA), at least 3 (severe CAA), or				

presence of capillary CAA, did not significantly affect the diagnostic performance (**Table 3**). In a subset of
participants with cognitive impairment (*n*= 42), the specificity of a "probable CAA" diagnosis improved at
the expense of sensitivity (**Supplemental Table 2**).

155 **Discussion:**

156 In this study, we explored the performance of the most recent iteration of the Boston criteria (v.2.0) in a 157 population of individuals without symptomatic ICH or TFNE. Our main finding is that while the Boston 158 criteria v2.0 improves sensitivity for CAA diagnosis (compared to v1.5), it comes with the expense of 159 specificity to an almost similar degree. The net effect is that both the Boston criteria v2.0 and v1.5 show 160 overall limited sensitivity and specificity and positive and negative predictive value in the setting of a 161 population presenting without characteristic hemorrhagic CAA syndromes. The diagnostic accuracy and 162 predictive value did not significantly improve when stratifying cases by varying grades of pathological 163 CAA, nor did it change with the inclusion of cognitive impairment as a criterion for possible or probable 164 CAA.

165 The performance in the population of our study is different from that observed in the recent 166 validation study of the Boston criteria v2.0, which showed improved sensitivity (74.5%) and high 167 specificity (95.0%) among patients who presented with spontaneous lobar hemorrhages, cognitive impairment, or TFNE (AUC 0.85).⁸ The Boston criteria were initially developed to determine the etiology 168 of spontaneous ICH and to predict the risk of recurrent hemorrhage.³ Thus, the Boston criteria may be 169 more accurate in and calibrated for identifying advanced (i.e., bleeding-prone) CAA pathology, which is 170 more likely to cause symptomatic lobar ICH.²³ Consistent with this hypothesis, a subgroup analysis in 171 172 the Boston criteria v2.0 validation study showed low sensitivity (55.1%) and high specificity (96.2%) for 173 predicting pathological CAA in cases presenting without ICH (but significantly improved compared to 174 prior Boston criteria versions). Of note, patients in this subgroup analysis had TFNE or cognitive impairment and therefore differed from our study population as a whole.⁸ This is also reflected in the 175 176 low prevalence of MRI markers of CAA in our population. Our data mirror a prior study that showed 177 overall low sensitivity and specificity of the Boston criteria v1.0 in both hospital- and population-based settings of elderly individuals without ICH.¹⁰ 178

179 The results of this study raise an important question about the clinical significance of incidental 180 imaging biomarkers of CAA in asymptomatic people or patients presenting in a memory-clinic setting 181 who have never experienced any symptomatic brain hemorrhage. Two large population-based studies 182 showed a high rate of any pathological CAA on autopsy (78.9%) in participants without symptoms of CAA other than cognitive impairment.⁹ The Boston criteria v2.0 are very accurate in correctly identifying 183 184 underlying CAA pathology in patients with symptomatic lobar hemorrhages or TFNE, but they may not 185 accurately predict less severe pathological CAA changes in patients with minimal or no symptoms. Our 186 findings require confirmation and further validation in larger population-based samples and patients 187 with cognitive impairment, but they suggest that clinicians should exercise caution when applying the 188 Boston criteria to an asymptomatic individual with a minimal incidental lobar CMB burden on brain 189 MRI.

190 Our study has several limitations. A key limitation, inherent to all similar diagnostic validation 191 studies in the field, is potential selection bias due to the requirement for neuropathological tissue. In 192 combination with the relatively small sample size, this might reduce the generalizability of our findings. 193 The use of GRE instead of SWI, which is less sensitive to blood-breakdown products and hence CMBs 194 detection, may have increased the false negative rate in our analysis. There was a high degree of 195 concomitant pathology in our population including Alzheimer's disease, Lewy body disease, TDP-43, and 196 4-repeat tauopathy; these are associated with different prevalence rates and degrees of underlying CAA. 197 Perivascular space rating was performed on T1-weighted sequences instead of T2-weighted sequences, 198 which reduced our ability to detect CSO-PVS. Our study used the Love consensus criteria instead of the Vonsattel method used in the *Lancet* paper,⁸ which may limit the comparability of the two studies. 199

200 Conclusion:

- 201 The Boston criteria v2.0 are accurate when applied to patients with cardinal CAA hemorrhagic
- 202 syndromes (symptomatic ICH or TNFE) and thus advanced disease, but the clinical relevance in
- 203 asymptomatic individuals or patients with cognitive impairment and incidental radiological markers of
- 204 CAA needs further exploration. Larger population-based studies should aim to assess our findings and
- 205 determine the relationship between radiological markers of CAA and pathological severity. Additional
- 206 biomarkers need to be identified to improve the detection of pathology on the milder end of the CAA
- 207 spectrum.
- 208 **Funding:** National Institute on Aging of (NIH) under Award Numbers K76AG057015, AG006786,
- AG011378, AG16574), the National Institute for Neurologic Disorders and Stroke NS097495, and the
 GHR Foundation.
- 211
- 212 Disclosures: D.S. Knopman serves on a Data Safety Monitoring Board for the DIAN study. He served on a
- 213 Data Safety monitoring Board for a tau therapeutic for Biogen but receives no personal compensation.
- He is a site investigator in the Biogen aducanumab trials. He is an investigator in a clinical trial sponsored
- by Lilly Pharmaceuticals and the University of Southern California. He serves as a consultant for Samus
- 216 Therapeutics, Roche, and Alzeca Biosciences but receives no personal compensation. R.C. Petersen
- serves as a consultant for Roche, Inc., Genentech Inc., Nestle, Inc., Eli Lilly and Co., and Eisai, Inc.,
- receives publishing royalties from Mild Cognitive Impairment (Oxford University Press, 2003), and
- 219 UpToDate. C. R. Jack, A. A. Rabinstein, R. R. Reichard, and P. Shemuri receive research support from the
- 220 NIH. . J. Graff-Radford serves on the DSMB for STROKENET and receives research support from the NIH.
- 221 The other authors declare no financial or other conflict of interest. The views expressed in the submitted
- article are those of the authors and not an official position of the institution or funder.

223 References:

- Charidimou A, Boulouis G, Gurol ME, Ayata C, Bacskai BJ, Frosch MP, Viswanathan A, Greenberg
 SM. Emerging concepts in sporadic cerebral amyloid angiopathy. *Brain : a journal of neurology*.
 2017;140:1829-1850. doi: 10.1093/brain/awx047
- 227 2. Greenberg SM, Charidimou A. Diagnosis of Cerebral Amyloid Angiopathy: Evolution of the
- 228 Boston Criteria. *Stroke*. 2018;49:491-497. doi: 10.1161/strokeaha.117.016990
- Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. *Neurology*. 2001;56:537-539. doi: 10.1212/wnl.56.4.537
- Linn J, Halpin A, Demaerel P, Ruhland J, Giese AD, Dichgans M, van Buchem MA, Bruckmann H,
 Greenberg SM. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy.
 Neurology. 2010;74:1346-1350. doi: 10.1212/WNL.0b013e3181dad605
- 235 5. Charidimou A, Boulouis G. Clinical Diagnosis of Probable Cerebral Amyloid Angiopathy:
- Diagnostic Accuracy Meta-Analysis of the Boston Criteria. *Stroke*. 2022;53:3679-3687. doi:
- 237 10.1161/strokeaha.122.039501

238 6. Charidimou A, Boulouis G, Haley K, Auriel E, van Etten ES, Fotiadis P, Reijmer Y, Ayres A, 239 Vashkevich A, Dipucchio ZY, et al. White matter hyperintensity patterns in cerebral amyloid 240 angiopathy and hypertensive arteriopathy. *Neurology*. 2016;86:505-511. doi: 241 10.1212/wnl.000000000002362 242 Charidimou A, Meegahage R, Fox Z, Peeters A, Vandermeeren Y, Laloux P, Baron JC, Jäger HR, 7. 243 Werring DJ. Enlarged perivascular spaces as a marker of underlying arteriopathy in intracerebral 244 haemorrhage: a multicentre MRI cohort study. J Neurol Neurosurg Psychiatry. 2013;84:624-629. 245 doi: 10.1136/jnnp-2012-304434 246 8. Charidimou A, Boulouis G, Frosch MP, Baron JC, Pasi M, Albucher JF, Banerjee G, Barbato C, 247 Bonneville F, Brandner S, et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a 248 multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. The Lancet 249 Neurology. 2022;21:714-725. doi: 10.1016/s1474-4422(22)00208-3 250 9. Boyle PA, Yu L, Nag S, Leurgans S, Wilson RS, Bennett DA, Schneider JA. Cerebral amyloid 251 angiopathy and cognitive outcomes in community-based older persons. *Neurology*. 252 2015;85:1930-1936. doi: 10.1212/wnl.000000000002175 253 10. Martinez-Ramirez S, Romero JR, Shoamanesh A, McKee AC, Van Etten E, Pontes-Neto O, Macklin 254 EA, Ayres A, Auriel E, Himali JJ, et al. Diagnostic value of lobar microbleeds in individuals without 255 intracerebral hemorrhage. Alzheimer's & dementia : the journal of the Alzheimer's Association. 256 2015;11:1480-1488. doi: 10.1016/j.jalz.2015.04.009 257 11. Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Boeve BF, Ivnik RJ, Tangalos EG, 258 Petersen RC, Rocca WA. The Mayo Clinic Study of Aging: design and sampling, participation, 259 baseline measures and sample characteristics. *Neuroepidemiology*. 2008;30:58-69. doi: 260 10.1159/000115751 Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, 261 12. 262 Barkhof F, Benavente OR, et al. Neuroimaging standards for research into small vessel disease 263 and its contribution to ageing and neurodegeneration. *The Lancet Neurology*. 2013;12:822-838. 264 doi: 10.1016/s1474-4422(13)70124-8 Charidimou A, Frosch MP, Al-Shahi Salman R, Baron JC, Cordonnier C, Hernandez-Guillamon M, 265 13. 266 Linn J, Raposo N, Rodrigues M, Romero JR, et al. Advancing diagnostic criteria for sporadic 267 cerebral amyloid angiopathy: Study protocol for a multicenter MRI-pathology validation of Boston criteria v2.0. Int J Stroke. 2019;14:956-971. doi: 10.1177/1747493019855888 268 269 14. Charidimou A, Linn J, Vernooij MW, Opherk C, Akoudad S, Baron JC, Greenberg SM, Jäger HR, Werring DJ. Cortical superficial siderosis: detection and clinical significance in cerebral amyloid 270 271 angiopathy and related conditions. Brain : a journal of neurology. 2015;138:2126-2139. doi: 272 10.1093/brain/awv162 273 15. Charidimou A, Jäger RH, Fox Z, Peeters A, Vandermeeren Y, Laloux P, Baron JC, Werring DJ. 274 Prevalence and mechanisms of cortical superficial siderosis in cerebral amyloid angiopathy. 275 Neurology. 2013;81:626-632. doi: 10.1212/WNL.0b013e3182a08f2c 276 Rouhl RP, van Oostenbrugge RJ, Knottnerus IL, Staals JE, Lodder J. Virchow-Robin spaces relate 16. to cerebral small vessel disease severity. J Neurol. 2008;255:692-696. doi: 10.1007/s00415-008-277 278 0777-у 279 17. Potter GM, Chappell FM, Morris Z, Wardlaw JM. Cerebral perivascular spaces visible on 280 magnetic resonance imaging: development of a qualitative rating scale and its observer reliability. Cerebrovasc Dis. 2015;39:224-231. doi: 10.1159/000375153 281 282 18. Graff-Radford J, Lesnick TG, Mielke MM, Constantopoulos E, Rabinstein AA, Przybelski SA, 283 Vemuri P, Botha H, Jones DT, Ramanan VK, et al. Cerebral Amyloid Angiopathy Burden and 284 Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes. J Alzheimers Dis. 285 2021;81:113-122. doi: 10.3233/jad-201536

- Vemuri P, Gunter JL, Senjem ML, Whitwell JL, Kantarci K, Knopman DS, Boeve BF, Petersen RC,
 Jack CR, Jr. Alzheimer's disease diagnosis in individual subjects using structural MR images:
- 288 validation studies. *NeuroImage*. 2008;39:1186-1197. doi: 10.1016/j.neuroimage.2007.09.073
- 289 20. Love S, Chalmers K, Ince P, Esiri M, Attems J, Jellinger K, Yamada M, McCarron M, Minett T,
 290 Matthews F, et al. Development, appraisal, validation and implementation of a consensus
 291 protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue.
 292 American journal of neurodegenerative disease. 2014;3:19-32.
- 293 21. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, Müller M. pROC: an open-source
 294 package for R and S+ to analyze and compare ROC curves. *BMC Bioinformatics*. 2011;12:77. doi:
 295 10.1186/1471-2105-12-77
- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening
 the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for
 reporting observational studies. *J Clin Epidemiol*. 2008;61:344-349. doi:
- 299 10.1016/j.jclinepi.2007.11.008
- Vonsattel JP, Myers RH, Hedley-Whyte ET, Ropper AH, Bird ED, Richardson EP, Jr. Cerebral
 amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study.
 Ann Neurol. 1991;30:637-649. doi: 10.1002/ana.410300503

303

Median age at MRI, years (IQR)	75 (65-80)
Female, no. (%)	13 (24)
Hypertension, no. (%) ⁺	25 (53)
Dyslipidemia, no. (%) †	29 (62)
Diabetes mellitus, no. (%) †	13 (28)
APOE ε4 carrier, no. (%)	28 (53)
Education, years (SD)	15.4 (2.8)
Mean MMSE at MRI, score (SD)	19.3 (7.5)
Median age at death, years (IQR)	77 (67-83)
Median time between MRI and autopsy, years (IQR)	2.0 (1.4-2.7)
Clinical diagnosis at MRI, no. (%)	
Cognitively unimpaired	12 (22)
Mild cognitive impairment	3 (6)
Dementia	39 (72)
Lobar CMB, no. (%)	
None	36 (66)
1 CMB	8 (15)
2 CMB	6 (11)
3 CMB	1 (2)
4+ CMB	3 (6)
Deep CMB, no. (%)	3 (6)
Cortical superficial siderosis presence, no. (%)	4 (7)
WMH-MS present, no. (%)	36 (66)
Enlarged CSO-PVS present, no. (%)	4 (7)
Primary neuropathological diagnosis, no. (%)	
Alzheimer's disease	30 (56)
Lewy body disease	11 (20)
FTLD-TDP	7 (13)
FTLD-tau	2 (4)
Primary age-related tauopathy	2 (4)

Table 1. Demographic, clinical and imaging characteristics of study participants.

Argyrophilic grain disease	1 (2)
Prion disease	1 (2)

[†]Data missing from 7 participants.

	Histopathologically verified CAA	
	Yes (<i>n</i> = 28)	No (<i>n</i> = 26)
Boston criteria v1.5 diagnosis, no. (%)		
Probable CAA	6 (21)	5 (19)
Any CAA (Possible + Probable)	8 (29)	10 (38)
Boston criteria v2.0 diagnosis, no. (%)		
Probable CAA	8 (29)	9 (35)
Any CAA (Possible + Probable)	21 (75)	16 (62)

Histopathologically verified CAA refers to a grade of 2 or higher in at least 1 of the sampled regions based on the Love consensus criteria²⁰. CAA=cerebral amyloid angiopathy; CMB=cerebral microbleed; WMH-MS=white matter hyperintensity multispot pattern; CSO-PVS=perivascular spaces in the centrum semiovale; FTLD=frontotemporal lobar degeneration; TDP=TAR DNA-binding protein 43; SD=standard deviation; IQR=interquartile range.

Table 2. Diagnostic performance of the Boston criteria v2.0 and v1.5 using histopathologically verified CAA as the reference standard.

	Probable CAA (vs. non-probable CAA)		Probable plus possible CAA (vs. no CAA)	
	Boston criteria v2.0	Boston criteria v1.5	Boston criteria v2.0	Boston criteria v1.5
Sensitivity	28.6% (13.2-48.7)	21.4% (8.30-41.0)	75.0% (55.1-89.3)	28.6% (13.2-48.7)
Specificity	65.3% (44.3-82.8)	80.8% (60.7-93.5)	38.5% (20.2-59.4)	61.5% (40.6-79.8)
PPV	47.1% (23.0-72.2)	54.6% (23.4-83.3)	56.8% (39.5-72.9)	44.4% (21.5-69.2)
NPV	46.0% (29.5-63.1)	48.8% (33.3-64.5)	58.8% (32.9-81.6)	44.4% (27.9-61.9)
AUC	0.47 (0.34-0.60)	0.51 (0.40-0.62)	0.57 (0.44-0.69)	0.45 (0.32-0.58)
Z= -0.94, p= 0.35		<i>Z</i> = 1.7,	<i>p</i> = 0.09	

Comparison of paired ROC are reported as a *Z*-statistic and *p*-value. CAA=cerebral amyloid angiopathy; PPV=positive predictive value; NPV=negative predictive value; AUC=area under the receiver operator characteristic curve.

Table 3. Diagnostic performance of the Boston criteria v2.0 for probable CAA vs. non probable CAA using different CAA neuropathologic grades of histopathologically verified CAA as the reference standard.

Histopathological features

-	≥ Grade 1 CAA	<u>></u> Grade 3 CAA	Capillary CAA present
Sensitivity	33.3% (19.6-49.6)	30.0% (11.9-54.3)	44.4% (21.5-69.2)
Specificity	75.0% (42.8-94.5)	67.6% (49.5-82.6)	75.0% (57.8-87.9)
PPV	82.4% (56.6-96.2)	35.3% (14.2-61.7)	47.1% (23.0-72.2)
NPV	24.3% (11.8-41.2)	62.2% (44.8-77.5)	73.0% (55.9-86.2)
AUC	0.54 (0.39-0.69)	0.49 (0.36-0.62)	0.60 (0.46-0.74)
Compared to	7-072 -047	7- 0 20 m- 0 84	7-12 m-010
<u>></u> grade 2 CAA	<i>Z</i> = -0.73, <i>p</i> = 0.47	<i>Z</i> = -0.20, <i>p</i> = 0.84	<i>Z</i> = -1.3, <i>p</i> = 0.19

Histopathological grades are based on the Love consensus criteria²⁰. Comparison of paired ROC are reported as a *Z*-statistic and *p*-value. CAA=cerebral amyloid angiopathy; PPV=positive predictive value; NPV=negative predictive value; AUC=area under the receiver operator characteristic curve.